Literature DB >> 7681242

Comparison between NK cell activity and prostate cancer stage and grade in untreated patients: correlation with tumor markers and hormonal serotest data.

M Tarle1, I Kraljić, M Kastelan.   

Abstract

NK cell activity was measured in 24 patients with untreated prostate cancer (11 subjects with localized disease, D0, and 13 patients with stage D tumor) and 10 healthy controls. In these same subjects serum prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), testosterone, prolactin and cortisol concentrations were assessed. The data obtained were correlated with both tumor spread (localized vs disseminated disease) and grade (well-differentiated cancer, G1, vs moderately and poorly differentiated carcinoma, G2 and G3). In patients with stage D0 cancer mean NK activity (33.0 +/- 10.6) was virtually identical with the mean value recorded in healthy men (34.5 +/- 7.1), while in subjects with stage D1-D2 disease NK activity was significantly reduced (11.9 +/- 7.1). These findings correspond with our data on treated subjects, in whom NK activity level was found to correlate well with the presence of tumor cells in the circulation. In subjects free of malignant tumors but with a chronic disease (diabetes, arthritis, severe rheumatic disorders) mean NK activity was clearly reduced (5.7 +/- 1.5). The use of NK activity data as a probe for tumor metastases was found to be statistically as reliable as was the application of the PSA serotest (but not serum PAP concentrations). None of the measured hormonal parameters correlated well with tumor stage. Both testosterone and prolactin serum concentrations were found to be lower in the G2 and G3 cancer group than in well-differentiated (G1) tumors, in accordance with the published literature.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7681242     DOI: 10.1007/bf00295186

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  14 in total

1.  Prediction of postoperative clinical course by autologous tumor-killing activity in lung cancer patients.

Authors:  A Uchida; Y Kariya; N Okamoto; K Sugie; T Fujimoto; M Yagita
Journal:  J Natl Cancer Inst       Date:  1990-11-07       Impact factor: 13.506

2.  A new PTP parameter as potential predictor of prostate cancer response to therapy.

Authors:  M Tarle
Journal:  Int J Rad Appl Instrum B       Date:  1988

3.  Clinical evidence for and implications of the multistep development of prostate cancer.

Authors:  H B Carter; S Piantadosi; J T Isaacs
Journal:  J Urol       Date:  1990-04       Impact factor: 7.450

4.  Cross-comparison of PSA and PAP values in a wide spectrum of prostate cancer conditions.

Authors:  M Tarle
Journal:  Anticancer Res       Date:  1988 Jul-Aug       Impact factor: 2.480

5.  Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients.

Authors:  T A Stamey; J N Kabalin; J E McNeal; I M Johnstone; F Freiha; E A Redwine; N Yang
Journal:  J Urol       Date:  1989-05       Impact factor: 7.450

6.  Correlation between bone scans and serum levels of osteocalcin, prostate-specific antigen, and prostatic acid phosphatase in monitoring patients with disseminated cancer of the prostate.

Authors:  M Tarle; K Kovaćić; A Strelkov-Alfirević
Journal:  Prostate       Date:  1989       Impact factor: 4.104

7.  Differential effects of growth factor antagonists on neoplastic and normal prostatic cells.

Authors:  R A Morton; J T Isaacs; W B Isaacs
Journal:  Prostate       Date:  1990       Impact factor: 4.104

8.  Role of natural killer cells in bladder tumor.

Authors:  H Tsujihashi; H Matsuda; S Uejima; T Akiyama; T Kurita
Journal:  Eur Urol       Date:  1989       Impact factor: 20.096

9.  NK cell activity in treated prostate cancer patients as a probe for circulating tumor cells: hormone regulatory effects in vivo.

Authors:  M Kastelan; I Kraljić; M Tarle
Journal:  Prostate       Date:  1992       Impact factor: 4.104

10.  [Natural killer (NK) activity of peripheral blood and regional lymph nodes in patients with genitourinary malignant tumors. 1. NK activity of peripheral blood in patients with genitourinary malignant tumors].

Authors:  M Yamashita; Y Kamei; Y Fujita
Journal:  Nihon Hinyokika Gakkai Zasshi       Date:  1989-05
View more
  6 in total

1.  Association of neutrophil-to-lymphocyte ratio and natural killer cell activity revealed by measurement of interferon-gamma levels in a healthy population.

Authors:  Bo-Ram Kim; Sejong Chun; Duck Cho; Kyeong-Hee Kim
Journal:  J Clin Lab Anal       Date:  2018-08-13       Impact factor: 2.352

2.  Clinical utility of a novel natural killer cell activity assay for diagnosing non-small cell lung cancer: a prospective pilot study.

Authors:  Sue In Choi; Seung Hyeun Lee; Ji-Young Park; Kyoung-Ah Kim; Eun Joo Lee; Sang Yeub Lee; Kwang Ho In
Journal:  Onco Targets Ther       Date:  2019-02-27       Impact factor: 4.147

3.  Can natural killer cell activity help screen patients requiring a biopsy for the diagnosis of prostate cancer?

Authors:  Bum Sik Tae; Byeong Jo Jeon; Young Hoon Lee; Hoon Choi; Jae Young Park; Jae Hyun Bae
Journal:  Int Braz J Urol       Date:  2020 Mar-Apr       Impact factor: 1.541

4.  Natural killer cell activity as a biomarker for the diagnosis of lung cancer in high-risk patients.

Authors:  Morten Borg; Sara Witting Christensen Wen; Torben Frøstrup Hansen; Anders Jakobsen; Rikke Fredslund Andersen; Ole Hilberg; Ulla Møller Weinreich; Line Nederby
Journal:  J Int Med Res       Date:  2022-06       Impact factor: 1.573

5.  Natural killer cell activity for IFN-gamma production as a supportive diagnostic marker for gastric cancer.

Authors:  Jongmi Lee; Ki Hyun Park; Ji Hyeong Ryu; Hyun Jin Bae; Aeran Choi; Hyeyoung Lee; Jihyang Lim; Kyungja Han; Cho Hyun Park; Eun Sun Jung; Eun-Jee Oh
Journal:  Oncotarget       Date:  2017-07-31

6.  Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels.

Authors:  LiJun Xu; XiaoDong Chen; MingJing Shen; Dong-Rong Yang; Laifu Fang; Guobin Weng; Ying Tsai; Peter C Keng; Yuhchyau Chen; Soo Ok Lee
Journal:  Mol Oncol       Date:  2018-01-24       Impact factor: 6.603

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.